jm + diseases   1

Of Course 23andMe's Plan Has Been to Sell Your Genetic Data All Along
Today, 23andMe announced what Forbes reports is only the first of ten deals with big biotech companies: Genentech will pay up to $60 million for access to 23andMe's data to study Parkinson's. You think 23andMe was about selling fun DNA spit tests for $99 a pop? Nope, it's been about selling your data all along.

testing  ethics  dna  genentech  23andme  parkinsons  diseases  health  privacy 
january 2015 by jm

Copy this bookmark:



description:


tags: